Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Compact case
Published by: International Institute for Management Development (IMD)
Originally published in: 2005
Version: 11.02.2005
Length: 2 pages
Data source: Published sources

Abstract

This is the second of a four-case series (IMD-3-1496 to IMD-3-1499). The (B) part of the series focuses on the outcome of the lawsuit against the South African government. But the demands from the non-government organisations (NGO''s) keep on coming and Garnier, the CEO of GlaxoSmithKline (GSK), is faced with some tough decisions to make. Should he allow licensing? How should he deal with parallel importation?
Location:
Industry:
Size:
Largest pharmaceutical company in the world, more than 100,000 employees
Other setting(s):
2001-2004

About

Abstract

This is the second of a four-case series (IMD-3-1496 to IMD-3-1499). The (B) part of the series focuses on the outcome of the lawsuit against the South African government. But the demands from the non-government organisations (NGO''s) keep on coming and Garnier, the CEO of GlaxoSmithKline (GSK), is faced with some tough decisions to make. Should he allow licensing? How should he deal with parallel importation?

Settings

Location:
Industry:
Size:
Largest pharmaceutical company in the world, more than 100,000 employees
Other setting(s):
2001-2004

Related